Sebastian Gensior

Europe’s biotech sector has always been fond of government grants. Programs like Horizon Europe, with its eye-watering €95.5 billion budget for research and innovation from 2021 to 2027, have kept the pipettes full and the lab coats spotless. National initiatives in Germany and France add to the mix,

Have you noticed something peculiar creeping into the corporate world? A proliferation of titles that sound less like professional roles and more like something you might overhear at the gym or a tactical training facility. This linguistic drift—from "teams" to "squads" and from "leaders&

Ah, the serial founder. That darling of venture capital, the endlessly inventive entrepreneur who builds company after company, racking up exits like trophies on a mantelpiece. Their LinkedIn profiles read like a highlight reel of bold visions, impressive exits, and the occasional stealth startup that never quite gets explained. But

The Weighted Average Cost of Capital (WACC) is a foundational metric in corporate finance, designed to evaluate the opportunity cost of capital and guide investment decisions. However, in the context of biotech and pharma—industries dominated by high uncertainty, skewed outcomes, and extreme risks—WACC becomes problematic. Its reliance on

The Capital Asset Pricing Model (CAPM) is one of the most widely used and taught frameworks in finance, offering a simplified approach to estimate the cost of equity. However, its application in biotech and pharma is deeply flawed. CAPM relies on assumptions of market efficiency, normal distributions, and systematic risk

It seems everyone these days is angling for a board seat. With the rise of startups and small businesses, LinkedIn profiles are awash with aspiring Non-Executive Directors (NEDs) and advisors, convinced their 15 or 25 years of corporate experience make them indispensable to young companies. The allure of wielding influence,

It seems everyone wants to be an investor these days. Armed with a LinkedIn bio touting "angel investor" or "venture partner," they scour startups for the next unicorn. Some manage portfolios ranging from $100,000 to $500,000—no small sum, but hardly the kind of

On January 12, 2025, the European Union’s Health Technology Assessment Regulation (HTAR) came into force, introducing a centralized framework for the evaluation of medicines and medical devices across Member States. At first glance, the regulation promises to streamline processes, eliminate duplication, and expedite patient access to innovative treatments. However,

The Chartered Alternative Investment Analyst (CAIA) designation positions itself as the key to unlocking the mysteries of hedge funds, private equity, and the murkier corners of finance. It’s the alternative to the alternative, a credential for those who scoff at traditional stock-and-bond strategies. For industries like biotech and pharma,

The Chartered Financial Analyst (CFA) designation once sat atop the financial world like a gold standard minted for modern markets. For decades, it promised to transform diligent candidates into masters of valuation, risk management, and portfolio optimization. But in 2024, the CFA faced a reality as unforgiving as its exams: